Review



plod2 antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    R&D Systems plod2 antibody
    Plod2 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab4445/Human+Lysine+Hydroxylase+2%2FPLOD2+Antibody/pm39710969-229-48-50
    Average 92 stars, based on 9 article reviews
    plod2 antibody - by Bioz Stars, 2026-09
    92/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Quantitative proteomics identifies secreted diagnostic biomarkers as well as tumor-dependent prognostic targets for clear cell Renal Cell Carcinoma
    Article Snippet: .. Primary antibody incubation was done overnight at 4 °C with following dilutions: anti-PLOD2 mouse at 1:500-1:1,000 (MAB4445, R&D Systems), anti-FERMT3 mouse at 1:500-1:1,500 (ab173416, Abcam), anti-SPARC mouse at 1:1,000 (33-5500, Invitrogen), anti-SIRPα rabbit at 1:1,500-1:3,500 (13379, Cell Signaling Technology) and anti-ACTB mouse at 1:5,000 (ab6276, Abcam). .. As secondary antibodies HRP-conjugated anti-mouse IgG at 1:2,000 (7076S, Cell Signaling Technologies) and HRP-conjugated anti-rabbit IgG at 1:2,000 (7074S, Cell Signaling Technologies) were used.

    Article Title: Quantitative proteomics identifies secreted diagnostic biomarkers as well as tumor-dependent prognostic targets for clear cell Renal Cell Carcinoma
    Article Snippet: .. Tissue sections were incubated with primary antibodies at 37 °C with following dilutions: anti-SPARC mouse at 1:800 (33-5500, Invitrogen), anti-SIRPα rabbit at 1:25 (13379, Cell Signaling Technology), anti-FERMT3 mouse at 1:2,500 (ab173416, Abcam) and anti-PLOD2 mouse at 1:250 (MAB4445, R&D Systems). .. The UltraView Detection kit (760-500, Ventana Medical Systems) was used for detection.

    Article Title: Quantitative Proteomics Identifies Secreted Diagnostic Biomarkers as well as Tumor-Dependent Prognostic Targets for Clear Cell Renal Cell Carcinoma
    Article Snippet: .. Tissue sections were incubated with primary antibodies at 37 C with following dilutions: anti-SPARC mouse at 1:800 (33-5500, Invitrogen), antiSIRPa rabbit at 1:25 (13379, Cell Signaling Technology), antiFERMT3 mouse at 1:2,500 (ab173416, Abcam) and anti-PLOD2 mouse at 1:250 (MAB4445, R&D Systems). .. The UltraView Detection kit (760–500, Ventana Medical Systems) was used for detection.



    Similar Products

    plod2 antibody  (R&D Systems)
    92
    R&D Systems plod2 antibody
    Plod2 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab4445/Human+Lysine+Hydroxylase+2%2FPLOD2+Antibody/pm39710969-229-48-50
    Average 92 stars, based on 1 article reviews
    plod2 antibody - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    anti plod2  (R&D Systems)
    92
    R&D Systems anti plod2
    Anti Plod2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab4445/Human+Lysine+Hydroxylase+2%2FPLOD2+Antibody/pm38335278-118-29-30
    Average 92 stars, based on 1 article reviews
    anti plod2 - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    mab4445  (R&D Systems)
    92
    R&D Systems mab4445
    Mab4445, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab4445/Human+Lysine+Hydroxylase+2%2FPLOD2+Antibody/10__1158_slash_1541___7786__mcr___21___0004-125-38-39
    Average 92 stars, based on 1 article reviews
    mab4445 - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    anti plod2 mouse  (R&D Systems)
    92
    R&D Systems anti plod2 mouse
    Anti Plod2 Mouse, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab4445/Human+Lysine+Hydroxylase+2%2FPLOD2+Antibody/10__1158_slash_1541___7786__mcr___21___0004-125-34-39
    Average 92 stars, based on 1 article reviews
    anti plod2 mouse - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    anti plod2 mouse monoclonal antibody  (R&D Systems Hematology)
    92
    R&D Systems Hematology anti plod2 mouse monoclonal antibody
    Clinicopathological characteristics of patient samples and expression of <t> PLOD2 </t> in laryngeal cancer
    Anti Plod2 Mouse Monoclonal Antibody, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab4445/Human+Lysine+Hydroxylase+2%2FPLOD2+Antibody/pmc06712771-144-4-11
    Average 92 stars, based on 1 article reviews
    anti plod2 mouse monoclonal antibody - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Clinicopathological characteristics of patient samples and expression of PLOD2 in laryngeal cancer

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: Clinicopathological characteristics of patient samples and expression of PLOD2 in laryngeal cancer

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques: Expressing

    The primer sequences were used in qRT-PCR

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: The primer sequences were used in qRT-PCR

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques:

    PLOD2, CD44, and CD133 mRNA expression levels and protein in 8 pairs of human LSCC tissues and matched adjacent nontumor tissues. a Relative PLOD2, CD44, and CD133 RNA expression in 8 pairs of LSCC tumor tissues (T) and matched adjacent nontumor tissues (N). b Relative PLOD2, CD44, and CD133 protein expression in human LSCC tumor tissues and matched adjacent nontumor tissues. α-Tubulin was measured as the loading control

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: PLOD2, CD44, and CD133 mRNA expression levels and protein in 8 pairs of human LSCC tissues and matched adjacent nontumor tissues. a Relative PLOD2, CD44, and CD133 RNA expression in 8 pairs of LSCC tumor tissues (T) and matched adjacent nontumor tissues (N). b Relative PLOD2, CD44, and CD133 protein expression in human LSCC tumor tissues and matched adjacent nontumor tissues. α-Tubulin was measured as the loading control

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques: Expressing, RNA Expression, Control

    IHC analysis of the expression levels of PLOD2, CD44, and CD133 in laryngeal tumor samples with different clinical stages (1, 2, 3 and 4), T stages (T1 & T2, T3 & T4), N stages (N0, N1-N3), and M stages (M0, M1). The expression of PLOD2, CD44 and CD133 was increased in the advanced-stage LSCC tumor tissues. Magnification: × 200

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: IHC analysis of the expression levels of PLOD2, CD44, and CD133 in laryngeal tumor samples with different clinical stages (1, 2, 3 and 4), T stages (T1 & T2, T3 & T4), N stages (N0, N1-N3), and M stages (M0, M1). The expression of PLOD2, CD44 and CD133 was increased in the advanced-stage LSCC tumor tissues. Magnification: × 200

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques: Expressing

    Correlation between PLOD2 expression and clinicopathological characteristics of laryngeal cancer patients

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: Correlation between PLOD2 expression and clinicopathological characteristics of laryngeal cancer patients

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques: Expressing

    Univariate and multivariate analysis of factors associated with overall survival in 114 laryngeal cancer patients

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: Univariate and multivariate analysis of factors associated with overall survival in 114 laryngeal cancer patients

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques:

    OS curves based on different PLOD2 expression levels. a Kaplan-Meier survival curves for LSCC patients with high PLOD2, CD44 and CD133 expression (red line) versus low PLOD2, CD44 and CD133 expression (blue line). b Kaplan-Meier survival curves for LSCC patients with high PLOD2 and CD44/CD133 expression (red line) versus low PLOD2 and CD44/CD133 expression (blue line)

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: OS curves based on different PLOD2 expression levels. a Kaplan-Meier survival curves for LSCC patients with high PLOD2, CD44 and CD133 expression (red line) versus low PLOD2, CD44 and CD133 expression (blue line). b Kaplan-Meier survival curves for LSCC patients with high PLOD2 and CD44/CD133 expression (red line) versus low PLOD2 and CD44/CD133 expression (blue line)

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques: Expressing

    Manifestations of PLOD2 maintaining CSC characteristics. a Hep-2 and FaDu cell lines were engineered for the overexpression or silencing of PLOD2. b The SP was analyzed in the different cell lines by multiparametric flow cytometry. c Hep-2 and FaDu cell spheres cultured in medium were photographed; representative images are shown. Scale bar = 50 μm. d The mRNA expression levels of genes representing CSC markers were upregulated. e The protein expression levels of genes representing CSC markers were upregulated. * P < 0.05

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: Manifestations of PLOD2 maintaining CSC characteristics. a Hep-2 and FaDu cell lines were engineered for the overexpression or silencing of PLOD2. b The SP was analyzed in the different cell lines by multiparametric flow cytometry. c Hep-2 and FaDu cell spheres cultured in medium were photographed; representative images are shown. Scale bar = 50 μm. d The mRNA expression levels of genes representing CSC markers were upregulated. e The protein expression levels of genes representing CSC markers were upregulated. * P < 0.05

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques: Over Expression, Flow Cytometry, Cell Culture, Expressing

    PLOD2 could promote drug resistance in laryngeal cancer cells. a Apoptotic scatter plot; Annexin V-FITC and PI staining of the indicated cells treated with DDP (50 μM) for 48 h. b IC50 of DDP in the indicated cells. Each bar represents the mean ± SD of five independent experiments. * P < 0.05. FITC, fluorescein isothiocyanate; PI, propidium iodide

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: PLOD2 could promote drug resistance in laryngeal cancer cells. a Apoptotic scatter plot; Annexin V-FITC and PI staining of the indicated cells treated with DDP (50 μM) for 48 h. b IC50 of DDP in the indicated cells. Each bar represents the mean ± SD of five independent experiments. * P < 0.05. FITC, fluorescein isothiocyanate; PI, propidium iodide

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques: Staining

    PLOD2 overexpression contributes to drug resistance in Hep-2 cells in vivo. a Representative photographs of tumors isolated from the experimental mice (with/without DDP treatment). b Cleaved caspase 3 was significantly decreased in PLOD2-overexpressing Hep-2 cells. c Tumor volumes of the experimental mice during the treatment period. Each bar represents the mean ± SD of five independent experiments

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: PLOD2 overexpression contributes to drug resistance in Hep-2 cells in vivo. a Representative photographs of tumors isolated from the experimental mice (with/without DDP treatment). b Cleaved caspase 3 was significantly decreased in PLOD2-overexpressing Hep-2 cells. c Tumor volumes of the experimental mice during the treatment period. Each bar represents the mean ± SD of five independent experiments

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques: Over Expression, In Vivo, Isolation

    PLOD2 overexpression could activate the Wnt signaling pathway. a The mRNA levels of downstream genes of the Wnt signaling pathway(c-myc, CD44, Snail, TCF4, and MMP-2) were upregulated by PLOD2. β-Actin was used as an internal control. b Dual luciferase assay showing the effect on TOP/FOP reporter activity in LSCC cells following the overexpression and silencing of PLOD2. c Immunoblot assay of c-myc, β-catenin, MDR-1, and MRP protein levels in LSCC cells transfected with PLOD2 and controls. GAPDH was used as an internal control

    Journal: BMC Cancer

    Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

    doi: 10.1186/s12885-019-6029-y

    Figure Lengend Snippet: PLOD2 overexpression could activate the Wnt signaling pathway. a The mRNA levels of downstream genes of the Wnt signaling pathway(c-myc, CD44, Snail, TCF4, and MMP-2) were upregulated by PLOD2. β-Actin was used as an internal control. b Dual luciferase assay showing the effect on TOP/FOP reporter activity in LSCC cells following the overexpression and silencing of PLOD2. c Immunoblot assay of c-myc, β-catenin, MDR-1, and MRP protein levels in LSCC cells transfected with PLOD2 and controls. GAPDH was used as an internal control

    Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

    Techniques: Over Expression, Control, Luciferase, Activity Assay, Western Blot, Transfection